Source: Leukocytes from donor’s blood.

Catalog No.: CYT-243

Introduction :

Human LeukinFeron is a combines preparation of natural cytokines involved in cellular reactions elimination of pathogen (antigen).  Treatment with LeukinFeron results in a reduced frequency of side effects caused by prospidine therapy.  Human LeukinFeron in the combined therapy of Kaposi’s sarcoma leads to a considerable improvement of the initially abnormal levels of immunocompetent and phagocytizing cells.
LF activates expression of HLA-Dr antigens on Human immune effectors and improve immune recognition.
LF provides the normalizing action on CD4/CD8 cells interaction and cytokine production by immunocompetent cells that is important for immunoreactivity.  LF is applied for the treatment of many viral diseases, bacterial infections, including sepsis, tuberculosis, chlamidial, mucoplasmic, herpetic infections and oncological diseases.

Description:

A single dose of Human LeukinFeron is prodced from 1million leukocytes isolated from doner’s blood contains natural IFN-alpha 10,000IU and a complex of cytokines from the first phase of the immune response at their natural ratio: IL-6, IL-12, TNF-alpha, MIF and LIF.

Physical Appearance:

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation:

Each Vial contains 0.1M NaCl and 1mg HSA.

Solubility:

The lyophilized LF is very soluble in water and most aqueous buffers.

Stability:

Lyophilized LF although stable at room temperature for 3 weeks, should be stored desiccated below -18 °C. Upon reconstitution LF should be stored at 4 °C between 2-7 days and for future use below -18 °C. Please prevent freeze-thaw cycles.

Usage:

Product is furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.